Aiforia in brief

Aiforia in brief

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.

Mission

Aiforia’s mission is to transform pathology with AI, enabling better care for each patient.

Vision

Aiforia envisions being the global leader in artificial intelligence-powered pathology image analysis.

Aiforia's users around the world

Aiforia's cloud platform is used globally

5,000+ users

Pathologists, medical scientists, and researchers use Aiforia's AI and image analysis tools worldwide.

50+ countries

Aiforia's cloud-based software and services are used in over 50 countries across the world.

1 million+ images

Over 1 million images have been analyzed, and thousands of AI models have been developed on Aiforia’s platform.

Business model

Aiforia has a scalable business model based on software-as-a-service (SaaS). Fees are both annual and usage-based. The annual fee covers use of the platform and depends on the amount of cloud storage and the number of users. Usage-based fees depend on the number of analyses and the complexity and size of the AI project, and, in most cases, customers pay them in advance as credits.

Aiforia earns revenue through two models:

  • Right to access: Customers use Aiforia’s cloud-based software for a fixed contract period. Revenue from SaaS, license maintenance, application support, and cloud storage is recognized evenly over that period.
  • Right to use: Customers receive a license installed in their own software environment. Revenue from the license and its installation is recognized at a single point in time, when the installed license is delivered at the start of the contract.

Credit income is recognized when customers use their credits, which are prepaid computing capacity. Any credits still unused at the end of the contract are recognized at that time. Revenue from tailored services, such as building AI models, is recognized upon completion of the work.

Because cloud services are outsourced, capital expenditure remains low, and there is ample capacity to meet customer demand.

Customer stickiness is high: once the software is integrated into a laboratory’s daily work, there is a strong motivation to keep using it.

Aiforia sells through several channels, using both direct and partner sales for preclinical and clinical customers.

Aiforia as an investment

Read about Aiforia as an investment

Key figures

See our financial development